The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer

Background: The EMPOWER-LUNG 3 clinical trial has shown that cemiplimab plus chemotherapy (CCT) significantly extended overall survival (OS) and progression-free survival (PFS) for patients with advanced non-small cell cancer (NSCLC) compared to placebo plus chemotherapy (PCT). However, the cost-eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Tingting, Huang, Yufan, Cai, Zhongjie, Lin, Wangchun, Chen, Xiaoxiao, Chen, Ruijia, Hu, Yingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409993/
https://www.ncbi.nlm.nih.gov/pubmed/37564176
http://dx.doi.org/10.3389/fphar.2023.1171302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409993/
https://www.ncbi.nlm.nih.gov/pubmed/37564176
http://dx.doi.org/10.3389/fphar.2023.1171302

Ejemplares similares